DECLARE‐TIMI 58: Participants’ baseline characteristics von Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P., Cahn, Avivit, Kato, Eri T., Silverman, Michael G., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P. H., Gause‐Nilsson, Ingrid A. M., Langkilde, Anna M., Johansson, Peter A., Sabatine, Marc S., Wiviott, Stephen D.

Volltext

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials von Jabbour, Serge, Seufert, Jochen, Scheen, Andre, Bailey, Clifford J., Karup, Cathrina, Langkilde, Anna M.

Volltext

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular... von McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna M., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John JV, DeMets, David L, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Langkilde, Anna Maria, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Sjöstrand, Mikaela, Solomon, Scott D, Diez, Mirta, Nicolau, Jose, Katova, Tzvetana, O'Meara, Eileen, Howlett, Jonathan, Verma, Subodh, Ge, Junbo, Belohlavek, Jan, Schou, Morten, Böhm, Michael, Merkely, Bela, Chopra, Vijay, Kitakaze, Masafumi, de Boer, Rudolf A., Drozdz, Jaroslaw, Tereshchenko, Sergey, Dukat, Andrej, Ljungman, Charlotta, Chiang, Chern‐En, Petrie, Mark, Desai, Akshay, Anand, Inder, Pham, Vinh Nguyen, Pfeffer, Marc A., Pocock, Stuart, Swedberg, Karl, Rouleau, Jean L., Chaturvedi, Nishi, Ivanovich, Peter, Levey, Andrew S., Christ‐Schmidt, Heidi, Held, Claes, Varenhorst, Christoph, Christersson, Christina, Mann, Johannes, Holmgren, Pernilla, Hallberg, Theresa, Langkilde, AnnaMaria, Sjöstrand, Mikaela, Denison, Hans, Reicher, Barry, Bengtsson, Olof, Fox, Ywonne, Forsby, Mikael, Alenhag, Eva‐Lena, Nilsson, Ann, Kazanowska, Kinga, Olofsson, Eva Lavik, Karup, Cathrine, Ekedahl‐Berggren, Maria, Klockargård, Anna‐Lena, Kempe, Karin, Selvén, Mathilda

Volltext

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial von Ostrominski, John W., Vaduganathan, Muthiah, Claggett, Brian L., Boer, Rudolf A., Desai, Akshay S., Dobreanu, Dan, Hernandez, Adrian F., Inzucchi, Silvio E., Jhund, Pardeep S., Kosiborod, Mikhail, Lam, Carolyn S.P., Langkilde, Anna M., Lindholm, Daniel, Martinez, Felipe A., O'Meara, Eileen, Petersson, Magnus, Shah, Sanjiv J., Thierer, Jorge, McMurray, John J.V., Solomon, Scott D.

Volltext

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular... von McMurray, John JV, DeMets, David L, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Langkilde, Anna M, Martinez, Felipe A, Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S, Sjöstrand, Mikaela, Solomon, Scott D, DAPA-HF Committees and Investigators

Volltext

Dapagliflozin in Patients with Chronic Kidney Disease von Heerspink, Hiddo J.L, Stefánsson, Bergur V, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E, McMurray, John J.V, Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D, Langkilde, Anna-Maria, Wheeler, David C

Volltext

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction von McMurray, John J.V, Solomon, Scott D, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Anand, Inder S, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Desai, Akshay S, Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E.A, Merkely, Béla, Nicolau, Jose C, O’Meara, Eileen, Petrie, Mark C, Vinh, Pham N, Schou, Morten, Tereshchenko, Sergey, Verma, Subodh, Held, Claes, DeMets, David L, Docherty, Kieran F, Jhund, Pardeep S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna-Maria

Volltext

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial von Heerspink, Hiddo J L, Stefansson, Bergur V, Chertow, Glenn M, Correa-Rotter, Ricardo, Greene, Tom, Hou, Fan-Fan, Lindberg, Magnus, McMurray, John, Rossing, Peter, Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C

Volltext

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes von Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Zelniker, Thomas A, Kuder, Julia F, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John P.H, Ruff, Christian T, Gause-Nilsson, Ingrid A.M, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna-Maria, Sabatine, Marc S

Volltext

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction von Solomon, Scott D., McMurray, John J.V., Claggett, Brian, de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Desai, Akshay S., Jhund, Pardeep S., Belohlavek, Jan, Chiang, Chern-En, Borleffs, C. Jan Willem, Comin-Colet, Josep, Dobreanu, Dan, Drozdz, Jaroslaw, Fang, James C., Alcocer-Gamba, Marco Antonio, Al Habeeb, Waleed, Han, Yaling, Cabrera Honorio, Jose Walter, Janssens, Stefan P., Katova, Tzvetana, Kitakaze, Masafumi, Merkely, Béla, O’Meara, Eileen, Saraiva, Jose Francisco Kerr, Tereshchenko, Sergey N., Thierer, Jorge, Vaduganathan, Muthiah, Vardeny, Orly, Verma, Subodh, Pham, Vinh Nguyen, Wilderäng, Ulrica, Zaozerska, Natalia, Bachus, Erasmus, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria

Volltext

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metf... von Bolinder, Jan, Ljunggren, Östen, Kullberg, Joel, Johansson, Lars, Wilding, John, Langkilde, Anna Maria, Sugg, Jennifer, Parikh, Shamik

Volltext

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease von Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J. V., Correa-Rotter, Ricardo, Rossing, Peter, Sjostrom, C. David, Stefansson, Bergur V., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J. L.

Volltext

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus von Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo H.M, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John P.H, Bonaca, Marc P, Ruff, Christian T, Desai, Akshay S, Goto, Shinya, Johansson, Peter A, Gause-Nilsson, Ingrid, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S, Wiviott, Stephen D

Volltext

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial von Heerspink, Hiddo J. L., Sjostrom, C. David, Jongs, Niels, Chertow, Glenn M., Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J., Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur, Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C.

Volltext

Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis von Block, Geoffrey A, Rosenbaum, David P, Leonsson-Zachrisson, Maria, Åstrand, Magnus, Johansson, Susanne, Knutsson, Mikael, Langkilde, Anna Maria, Chertow, Glenn M

Volltext

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study von Cahn, Avivit, Mosenzon, Ofri, Wiviott, Stephen D., Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L., Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P. H., Gause-Nilsson, Ingrid A. M., Fredriksson, Martin, Johansson, Peter A., Langkilde, Anna Maria, Sabatine, Marc S., Raz, Itamar

Volltext

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial von Wiviott, Stephen D., Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A., McGuire, Darren K., Wilding, John PH, Gause-Nilsson, Ingrid AM, Langkilde, Anna Maria, Johansson, Peter A., Sabatine, Marc S.

Volltext

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial von Mathieu, Chantal, Dandona, Paresh, Gillard, Pieter, Senior, Peter, Hasslacher, Christoph, Araki, Eiichi, Lind, Marcus, Bain, Stephen C, Jabbour, Serge, Arya, Niki, Hansen, Lars, Thorén, Fredrik, Langkilde, Anna Maria

Volltext

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 von Mosenzon, Ofri, Wiviott, Stephen D., Heerspink, Hiddo J. L., Dwyer, Jamie P., Cahn, Avivit, Goodrich, Erica L., Rozenberg, Aliza, Schechter, Meir, Yanuv, Ilan, Murphy, Sabina A., Zelniker, Thomas A., Gause-Nilsson, Ingrid A. M., Langkilde, Anna Maria, Fredriksson, Martin, Johansson, Peter A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P. H., Sabatine, Marc S., Raz, Itamar

Volltext

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial von Persson, Frederik, Rossing, Peter, Vart, Priya, Chertow, Glenn M., Hou, Fan Fan, Jongs, Niels, McMurray, John J., Correa-Rotter, Ricardo, Bajaj, Harpreet S., Stefansson, Bergur, Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J. L.

Volltext